Lymphoma Clinical Trials

Showing 361-380 of 2,926 trials

A Clinical Study of Allogenic CD19-CAR-T in the Treatment of R/R B-Cell Hematologic Malignancies

NCT07316907

This is a single-arm, open-label pilot study to evaluate the safety and efficacy of CD19-targeted allogenic CAR-T cells (19UCART) in patients with relapsed/refractory B-cell hematologic malignancies. 12 patients are planned to be enrolled in the dose-escalation trial. The primary objective of the study is to evaluation of the safety and feasibility of 19UCART for the treatment of relapsed/refractory B-cell hematologic malignancies. The secondary objective is to evaluate the efficacy of 19UCART for the treatment of relapsed/refractory B-cell hematologic malignancies. The exploratory objective is to evaluate expansion, persistence and ability of 19UCART to deplete CD19 positive cells in patients with relapsed/refractory B-cell hematologic malignancies.

Hematologic MalignanciesLymphoma

YANRU WANG12 participantsStarted Dec 2025

Zhenjiang, Jiangsu, China

RECRUITINGPhase 1/2

Study of ZG005 in Combination With Gecacitinib in Patients With Relapsed or Refractory Lymphoma

NCT06883526

PART 1: 1. To explore the safety of ZG005 in combination with Gecacitinib in patients with relapsed or refractory lymphoma. 2. To determine the recommended Phase II dosing regimen for relapsed or refractory lymphoma. PART 2: To evaluate the efficacy of ZG005 in combination with Gecacitinib in patients with relapsed or refractory lymphoma.

Lymphoma

Suzhou Zelgen Biopharmaceuticals Co.,Ltd60 participantsStarted May 2025

Hangzhou, Zhejiang, China

COMPLETEDPhase 2

Study of the Angiogenesis by PET/CT in Patients With Lymphoma

NCT02490891

The aim of the study is to measure tumoral angiogenesis modifications by RGD-K5 PET/CT before and after 2 cycles of chemotherapy in patients with lymphoma and a large tumoral mass

Lymphoma

Centre Henri Becquerel21 participantsStarted Nov 2015

Rouen, France

A Clinical Study of Allogenic CD19-CAR-T in the Treatment of R/R B-Cell Hematologic Malignancies

Study of ZG005 in Combination With Gecacitinib in Patients With Relapsed or Refractory Lymphoma

Study of the Angiogenesis by PET/CT in Patients With Lymphoma

Related Searches

GSL Synthetase Inhibitor Eliglustat Combined With CD30 Target Immunotherapy for the Treatment of of CD30+ Lymphoma

A Combination of Rituximab and CC-99282 as Front-line Therapy for Older Frail Patients With Diffuse Large B-cells Non-Hodgkin Lymphoma Evaluated With a Simplified Geriatric Assessment (sGA): a Phase II Study of the Fondazione Italiana Linfomi (FIL)

Clinical Study of LV009 Injection for the Treatment of Relapsed/Refractory CD19-Positive Hematologic and Lymphoid Malignancies

A Study of Mosunetuzumab Alone or With Zanubrutinib in People With Follicular Lymphoma

Study of the Clearance of Minimal Residual Disease Measured at the End of First-line Treatment in Patients With Lymphoma

Daratumumab and Ibrutinib for the Treatment of Relapsed or Refractory Chronic Lymphocytic Leukemia, DIRECT Study

Copanlisib and Nivolumab in Treating Patients With Richter's Transformation or Transformed Indolent Non-Hodgkin Lymphoma

Cholecalciferol in Improving Survival in Patients With Newly Diagnosed Cancer With Vitamin D Insufficiency

A Prospective, Observational Cohort Study on the Clinical Impact of Novel Monoclonal Antibodies in B-cell Non-Hodgkin Lymphoma in Italian Clinical Practice

Anti-CD7 CAR-T Cells in Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia or Lymphoma

Autologous HuCART19 T Cells Manufactured Using the CliniMACS Prodigy Platform for Pediatric B-ALL (huCART19 Prodigy)

A Study of DZD8586 Combination in CLL/SLL (TAI-SHAN10)

Real World Experience With Mogamulizumab in the Treatment of Cutaneous T-cell Lymphoma

Anti-CCR9 CAR T Cells for T Cell Leukaemia/Lymphoma

A Study of Usage of Brigatinib in the Treatment of Adult Participants for Approved Indications In South Korea

Preliminary Safety and Tolerability of CD19x22 CAR T Cells in Adolescent and Adult R/R B-NHL Patients

Bispecific CAR T Cells for B-cell Malignancies (BaseCAR-01 Trial)